Legal News

Commission greenlights AstraZeneca's $US 39bn acquisition of Alexion

Published on: 07 July 2021
Published by LNB News

LNB News 07/07/2021

Document Information

Issue Date: 07 July 2021

Published Date: 07 July 2021

Jurisdiction(s): United Kingdom

Article summary

The European Commission has approved, under Regulation (EC) 139/2004 (the EU Merger Regulation), the acquisition of US-based Alexion Pharmaceuticals Inc (Alexion) by UK's AstraZeneca plc (AstraZeneca) for $US 39bn. Although both are global pharmaceutical companies, Alexion focuses on the treatment of rare diseases and ​AstraZeneca focuses on common diseases. The Commission concluded that the merger would have limited impact on the markets involved.

Popular documents